EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Klebsiella pneumoniae carbapenemase variants: the new threat to global public health

Li Ding iD, Siquan Shen iD, Jing Chen, Zhen Tian, Qingyu Shi, Renru Han, Yan Guo iD, Fupin Hu iD

Clinical Microbiology Reviews · 20.12.2023 · 36 (4)

DOI: 10.1128/cmr.00008-23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 20.12.2023. Verfasst von Li Ding und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Public Health. Die Arbeit wurde bisher 227-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China (NSFC), China Antimicrobial Surveillance Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Klebsiella pneumoniae carbapenemase (KPC) variants, which refer to the substitution, insertion, or deletion of amino acid sequence compared to wild bla KPC type, have reduced utility of ceftazidime-avibactam (CZA), a pioneer antimicrobial agent in treating carbapenem-resistant Enterobacterales infections. So far, more than 150 bla KPC variants have been reported worldwide, and most of the new variants were discovered in the past 3 years, which calls for public alarm. The KPC variant protein enhances the affinity to ceftazidime and weakens the affinity to avibactam by changing the KPC structure, thereby mediating bacterial resistance to CZA. At present, there are still no guidelines or expert consensus to make recommendations for the diagnosis and treatment of infections caused by KPC variants. In addition, meropenem-vaborbactam, imipenem-relebactam, and other new β-lactam-β-lactamase inhibitor combinations have little discussion on KPC variants. This review aims to discuss the clinical characteristics, risk factors, epidemiological characteristics, antimicrobial susceptibility profiles, methods for detecting bla KPC variants, treatment options, and future perspectives of bla KPC variants worldwide to alert this new great public health threat.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaePublic HealthMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-Lactamase InhibitorsDrug Combinations

Stichwörter der Autor:innen

Klebsiella pneumoniaeblaKPC variantsceftazidime-avibactam

Substanzen

carbapenemaseAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-Lactamase InhibitorsDrug Combinations

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
  • Hangzhou Matridx Biotechnology Co., Ltd., Hangzhou, Zhejiang, China.

ORCID-Profile: Li Ding, Siquan Shen, Yan Guo, Fupin Hu

Förderung

  • National Natural Science Foundation of China (NSFC)
  • China Antimicrobial Surveillance Network

Zitieren

APA

Ding, L., Shen, S., Chen, J., Tian, Z., Shi, Q., Han, R., Guo, Y., & Hu, F. (2023). Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clinical Microbiology Reviews, 36(4). https://doi.org/10.1128/cmr.00008-23

Vancouver

Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clinical Microbiology Reviews. 2023;36(4). doi:10.1128/cmr.00008-23

BibTeX
@article{Ding2023,
  author = {Ding, Li and Shen, Siquan and Chen, Jing and Tian, Zhen and Shi, Qingyu and Han, Renru and Guo, Yan and Hu, Fupin},
  title = {Klebsiella pneumoniae carbapenemase variants: the new threat to global public health},
  journal = {Clinical Microbiology Reviews},
  year = {2023},
  volume = {36},
  number = {4},
  doi = {10.1128/cmr.00008-23}
}
Kostenlos starten →